Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–10.

Article  CAS  PubMed  Google Scholar 

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–80.

Article  CAS  PubMed  Google Scholar 

Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 2002;3:655–64.

Article  CAS  PubMed  Google Scholar 

Cho H, Nishida T, Takahashi T, Masuzawa T, Hirota S. Impact of the KIT/PDGFRA genotype on prognosis in imatinib-naïve Japanese patients with gastrointestinal stromal tumor. Ann Gastroenterol Surg. 2022;6:241–8.

Article  PubMed  Google Scholar 

Blay JY, Kang YK, Nishida T, von Mehren M. Gastrointestinal stromal tumours. Nat Rev Dis Primers. 2021;7:22.

Article  PubMed  Google Scholar 

Gotohda N, Nishida T, Sato S, Ozaka M, Nakahara Y, Komatsu Y, et al. Re-appraisal of the universal definition of tumor rupture among patients with high-risk gastrointestinal stromal tumors. Ann Gastroenterol Surg. 2023;7:1021–31.

Article  PubMed  PubMed Central  Google Scholar 

Klug LR, Khosroyani HM, Kent JD, Heinrich MC. New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nat Rev Clin Oncol. 2022;19:328–41.

Article  PubMed  PubMed Central  Google Scholar 

Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.

Article  CAS  PubMed  Google Scholar 

Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620–5.

Article  CAS  PubMed  Google Scholar 

Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626–32.

Article  CAS  PubMed  Google Scholar 

Yeh CN, Wang SY, Tsai CY, Chen YY, Liu CT, Chiang KC, et al. Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: a prospective cohort study. Int J Surg. 2017;39:30–6.

Article  PubMed  Google Scholar 

Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. Eur J Cancer. 2014;50:1772–8.

Article  PubMed  Google Scholar 

Fairweather M, Balachandran VP, Li GZ, Bertagnolli MM, Antonescu C, Tap W, et al. Cytoreductive surgery for metastatic gastrointestinal stromal tumors treated with tyrosine kinase inhibitors: a 2-institutional analysis. Ann Surg. 2018;268:296–302.

Article  PubMed  Google Scholar 

Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol. 2024;25:29–41.

Article  Google Scholar 

Aso K, Gohda Y, Hotta M, Minamimoto R, Shimizu Y, Uemura Y, et al. Clinical effectiveness of preoperative 18F-FDG PET/CT in predicting pathological tumor grade in patients with pseudomyxoma peritonei originating from appendix: a retrospective cohort study. Ann Surg Oncol. 2024;31:1990–5.

Article  PubMed  Google Scholar 

Zhang S, Sun L, Cai D, Liu G, Jiang D, Yin J, et al. ASO visual abstract: development and validation of PET/CT-based nomogram for preoperative prediction of lymph node status in esophageal squamous cell carcinoma. Ann Surg Oncol. 2024;31:3864–5.

Article  Google Scholar 

Hsu PP, Sabatini DM. Cancer cell metabolism: warburg and beyond. Cell. 2008;134:703–7.

Article  CAS  PubMed  Google Scholar 

Kitajima K, Nakajo M, Kaida H, Minamimoto R, Hirata K, Tsurusaki M, et al. Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: an update. Nagoya J Med Sci. 2017;79:527–43.

PubMed  PubMed Central  Google Scholar 

Shima T, Taniguchi K, Inomata Y, Arima J, Lee SW. Glycolysis in gastrointestinal stromal tumor: a brief overview. Neoplasia. 2024;55:101022.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17–21.

CAS  PubMed  Google Scholar 

Kaneta T, Takahashi S, Fukuda H, Arisaka Y, Oriuchi N, Hayashi T, et al. Clinical significance of performing 18F-FDG PET on patients with gastrointestinal stromal tumors: a summary of a Japanese multicenter study. Ann Nucl Med. 2009;23:459–64.

Article  PubMed  Google Scholar 

Yokoyama K, Tsuchiya J, Nakamoto Y, Tateishi U. Additional value of [(18)F]FDG PET or PET/CT for response assessment of patients with gastrointestinal stromal tumor undergoing molecular targeted therapy: a meta-analysis. Diagnostics (Basel). 2021;11:475.

Article  CAS  PubMed  Google Scholar 

Kim SJ, Lee SW. Performance of F-18 FDG PET/CT for predicting malignant potential of gastrointestinal stromal tumors: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2018;33:576–82.

Article  PubMed  Google Scholar 

Hwang SH, Jung M, Jeong YH, Jo K, Kim S, Wang J, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative (18)F-FDG PET/CT in patients with localized primary gastrointestinal stromal tumors. Cancer Metab. 2021;9:8.

Article  PubMed  PubMed Central  Google Scholar 

Cho MH, Park CK, Park M, Kim WK, Cho A, Kim H. Clinicopathologic features and molecular characteristics of glucose metabolism contributing to 1⁸f-fluorodeoxyglucose uptake in gastrointestinal stromal tumors. PLoS ONE. 2015;10:e0141413.

Article  PubMed  PubMed Central  Google Scholar 

Nishida T, Hirota S, Yanagisawa A, Sugino Y, Minami M, Yamamura Y, et al. Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int J Clin Oncol. 2008;13:416–30.

Article  PubMed  Google Scholar 

Hasegawa J, Kanda T, Hirota S, Fukuda M, Nishitani A, Takahashi T, et al. Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int J Clin Oncol. 2007;12:212–7.

Article  PubMed  Google Scholar 

Wada N, Takahashi T, Kurokawa Y, Nakajima K, Nishida T, Koh M, et al. Clinical significance of surgical intervention for imatinib-resistant gastrointestinal stromal tumors in the era of multiple tyrosine kinase inhibitors. Surg Today. 2021;51:1506–12.

Article  CAS  PubMed  Google Scholar 

Hirota S, Tateishi U, Nakamoto Y, Yamamoto H, Sakurai S, Kikuchi H, et al. English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology. Int J Clin Oncol. 2024;29:647–80.

Article  PubMed  PubMed Central  Google Scholar 

Makino T, Yamasaki M, Tanaka K, Tatsumi M, Takiguchi S, Hatazawa J, et al. Importance of positron emission tomography for assessing the response of primary and metastatic lesions to induction treatments in T4 esophageal cancer. Surgery. 2017;162:836–45.

Article  PubMed  Google Scholar 

Crișan G, Moldovean-Cioroianu NS, Timaru DG, Andrieș G, Căinap C, Chiș V (2022) Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade. Int J Mol Sci 23

Ohshima K, Morii E (2021) Metabolic reprogramming of cancer cells during tumor progression and metastasis. Metabolites

Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lewitowicz P, Matykiewicz J, Koziel D, Chrapek M, Horecka-Lewitowicz A, Gluszek S. CD63 and GLUT-1 overexpression could predict a poor clinical outcome in GIST: a study of 54 cases with follow-up. Gastroenterol Res Pract. 2016;2016:6478374.